Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Chan

Showing results (201-210 of 263) with videos related to

Pageof 27
Sort By:
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Nature Medicine|January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trialYasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Communications Medicine|May 16, 2024
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACsDonglu Zhang, Bin Ma, Peter S Dragovich, et al.
Theranostics|February 23, 2024
Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5Kondapa Naidu Bobba, Anil P Bidkar, Anju Wadhwa, et al.
Histopathology|December 24, 2022
Clear cell renal cell carcinoma with focal psammomatous calcifications: a rare occurrence mimicking translocation carcinomaAnkur R Sangoi, Khaleel I Al-Obaidy, Liang Cheng, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinomaLipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
European Urology Oncology|July 20, 2023
Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer SubtypesMeera R Chappidi, Martin Sjöström, Nancy Y Greenland, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
JAMA|April 5, 2012
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialSteven R Alberts, Daniel J Sargent, Suresh Nair, et al.
Pageof 27

Showing results (201-210 of 263) with videos related to

Sort By:
Pageof 27
Journal of the National Cancer Institute|June 14, 2014
Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147Wilson I Gonsalves, Michelle R Mahoney, Daniel J Sargent, et al.
Nature Medicine|January 4, 2024
Sotorasib with panitumumab in chemotherapy-refractory KRAS<sup>G12C</sup>-mutated colorectal cancer: a phase 1b trialYasutoshi Kuboki, Marwan Fakih, John Strickler, et al.
Communications Medicine|May 16, 2024
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACsDonglu Zhang, Bin Ma, Peter S Dragovich, et al.
Theranostics|February 23, 2024
Development of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5Kondapa Naidu Bobba, Anil P Bidkar, Anju Wadhwa, et al.
Histopathology|December 24, 2022
Clear cell renal cell carcinoma with focal psammomatous calcifications: a rare occurrence mimicking translocation carcinomaAnkur R Sangoi, Khaleel I Al-Obaidy, Liang Cheng, et al.
Cancer Chemotherapy and Pharmacology|October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinomaLipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
The Lancet. Oncology|August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trialDominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
European Urology Oncology|July 20, 2023
Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer SubtypesMeera R Chappidi, Martin Sjöström, Nancy Y Greenland, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
JAMA|April 5, 2012
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trialSteven R Alberts, Daniel J Sargent, Suresh Nair, et al.
Pageof 27